Letzte Aktualisierung: 06.05.2026

Akute myeloblastische Leukämie [AML] [C92.0]

AMLSG 34-23 / HOVON 173

Aktive Studien

Studieninformationen

Ivosidenib and Azacitidine With or Without enetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

Behandlungszentren im CIO

Bonn


Ziele

Primäres Prüfziel

EFS in patients with newly diagnosed IDH1-mutated AML, measured from the date of randomization to the date of treatment failure, hematologic relapse from CR/CRh or death from any cause, whichever occurs first; treatment failure is defined as not achieving either CR or CRh by week 24.

Sekundäre Prüfziele für die Behandlungsarme:

-

OS in patients with newly diagnosed IDH1-mutated AML, measured from the date of randomization to the date of death from any cause.

-

Rate of CR/CRh in patients with newly diagnosed IDH1-mutated AML, defined as the proportion of AML patients with CR/CRh at any time point during on-treatment period.



Design

Design

—

Phase

III

Zentren

Multizentrisch

Datenerhebung

Prospektiv

Interventionsgruppen

Zweiarmig

Verblindung

Doppelblind

Erkrankung

Diagnose

Akute myeloblastische Leukämie [AML] [C92.0]

Diagnosenbeschreibung

Patient with newly diagnosed IDH1-mutated AML, or IDH1-mutated MDS/AML

Mutation

—

Patienten

Alter

18 - 99 Jahre

Einschlusskriterien

Patient with newly diagnosed IDH1-mutated AML, or IDH1-mutated MDS/AML


Patient is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:

•

≥ 75 years of age ineligible for intensive chemotherapy per physician’s discretion (with an ECOG performance status 0-2; Appendix C).

•

18-74 years: patient is not eligible for standard chemotherapy because of any of the following co-morbidities:

o

ECOG performance status 2 or 3 (Appendix C).

o

Cardiac history of chronic heart failure requiring treatment; or with an ejection fraction ≤50%; or chronic stable angina.

o

Diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% or FEV1 ≤ 65%.

o

Creatinine clearance ≥ 30 mL/min to <45 ml/min calculated by the Cockcroft Gault formula.o

Moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 x upper limit of normal (ULN).

o

Any other comorbidity that the local physician assesses to be incompatible with intensive chemotherapy. If a patient meets this criterion, sponsor must be informed via HO173@erasmusmc.nl.

Ausschlusskriterien

1.

Patient has previously been treated for AML; a treatment period with hydroxyurea to control WBC counts is allowed; prior treatment with a hypomethylating agent for MDS-EB is not allowed; prior treatment with erythropoiesis-stimulating agents or luspatercept for MDS is allowed.

2.

Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.2); PML-RARA; or one of the other pathognomonic variant chromosomal translocations / fusion genes.

3.

AML with BCR-ABL1; or myeloid blast crisis of CML.

Therapie

Intervention

—

Substanz

—

Zuständige Gesamtstudie

Sponsor

—

Leiter der klinischen Prüfung (LKP)

—

Studiengruppen/-zentrale

—

Kontakt Klinische Studien

CIO Aachen: Uniklinik RWTH Aachen, +49 (0) 241 80-85490

CIO Bonn: Uniklinik Bonn, +49 (0) 228 287-16036

CIO Köln: Uniklinik Köln, +49 (0) 221 478-0

CIO Düsseldorf: Uniklinik Düsseldorf, +49 (0) 211 81-04150 (Mo-Do)